A Study of a Melatonin Receptor Agonist to Prevent Migraine

This study has been terminated.
(Recruitment slow and administrative reasons)
Sponsor:
Collaborator:
Takeda
Information provided by (Responsible Party):
Swedish Medical Center
ClinicalTrials.gov Identifier:
NCT00739024
First received: August 19, 2008
Last updated: August 22, 2012
Last verified: August 2012

August 19, 2008
August 22, 2012
April 2008
April 2009   (final data collection date for primary outcome measure)
T-Test [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
It was planned to use a simple T-Test or ANoVa for data analysis. No Analysis was made due to insufficient recruitment. Planned primary efficacy variable was the percent reduction in the average monthly miqraine/probable migraine frequency from the baseline period to the entire double-blind treatment phase of the study.
The primary efficacy variable is the percent reduction in the average monthly migraine/probable migraine frequency from the baseline period to the entire double-blind treatment phase of the study quantified by the number of attacks. [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00739024 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of a Melatonin Receptor Agonist to Prevent Migraine
A Randomized, Double-blind Placebo-controlled, Parallel Group Study to Study the Efficacy and Tolerability of Ramelteon (Rozerem) in the Prophylaxis of Migraine

The purpose of this study is to see if ramelteon will reduce the number of migraine headaches over a 12 week period. The safety and tolerability of ramelteon will also be evaluated. Ramelteon has been approved by the U.S. Food and Drug Administration (FDA) for insomnia (trouble sleeping); however; ramelteon has not been approved for the prevention of migraines.

Sleep has played an important role in migraine. Younger migraine sufferers usually report relief of migraine after sleep. In older migraine sufferers migraine is sometimes triggered with sleep changes. Occurrence of migraine in the early morning is very common. Therefore in these individuals regulation of sleep may improve the frequency of migraine. Recent PET studies done during migraine demonstrated activation of hypothalamus during migraine. In light of this new data and the known action of ramelteon on the melatonin receptors it may theoretically provide an insight on a possible mechanism of action in migraine.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
  • Migraine
  • Migraine With Aura
  • Migraine Without Aura
  • Drug: Ramelteon
    8 mg tablet, oral, once daily
    Other Name: Rozerem
  • Drug: Placebo
    Placebo tablet, oral, once daily
  • Active Comparator: Active Treatment
    Ramelteon once daily (double-blind assignment)
    Intervention: Drug: Ramelteon
  • Placebo Comparator: Placebo
    Placebo tablet, once daily (double-blind assignment)
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
18
September 2010
April 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female, ages 18 to 65 years, inclusive.
  • An established history of migraine, with or without aura and probable migraine, conforming to the revised IHS criteria (2004) for at least 1 year before screening, sufficient to establish the diagnosis.
  • To be randomized, during the prospective 4-week baseline period (approximately 28 days before Visit 2), subjects must have more than 4 migraine/probable migraine attacks per month (using the 24-hour rule).
  • Must have been less than 50 years of age at the time of initial migraine onset.
  • Must have no clinically significant and relevant abnormalities on physical or neurologic examinations
  • Must have completed a washout of all prophylactic medications for migraine before the start of the 4-week prospective baseline period (ie, 28 days before Visit 2, when randomization occurs).
  • Female subjects must be at least 1 of the following:
  • postmenopausal, or
  • surgically incapable of being children, or
  • practicing a highly effective method of birth control

Exclusion Criteria:

  • Most frequent type of headache does not meet the revised IHS diagnostic criteria for migraine with aura or without aura or probable migraine.
  • Pregnant or lactating women, or sexually active women of childbearing potential who are not using an appropriate method of contraception.
  • Failed adequate trials of prophylactic agents with demonstrated or possible efficacy in the prophylaxis of migraine. These agents include beta-blockers, tricyclic antidepressants, valproate, topiramate, and methysergide.
  • Unable to complete the diary in a timely and accurate manner after each migraine headache attacks, either independently or with assistance.
  • Overuse of analgesics or specific agents for abortive treatment of migraine attacks, which makes the investigator suspect medication overuse headache.
  • Receiving non-pharmacological prophylactic treatments such as acupuncture, chiropractic, or massage, if these were started less than 1 month before the screening visit (Day -28). These therapies may be continued if started before that time.
  • Currently abusing alcohol or other drugs.
  • Have a central nervous system neoplasm or infection, demyelinating disease, degenerative or progressive central nervous system disease, or active epilepsy.
  • History of serious systemic disease, including hepatic insufficiency, renal insufficiency, a malignant neoplasm, any disorder in which prognosis for survival is less than 3 months, or any disorder which in the judgment of the investigator will place the subject at excessive risk by participation in a controlled trial.
  • Have a significant psychiatric disorder, such as acute psychosis, schizophrenia, severe bipolar disorder, or severe unipolar mood disorder, of sufficient severity to preclude safe and effective participation of the subject in the study.
  • Require continued use of any of protocol-defined prohibited medications during the study
  • Have any recent or remote history of suicide attempt or ideation
  • Known or strongly suspected to be non-compliant in administering daily medications.
  • Received an experimental drug or used an experimental device within 30 days before the Screening Visit.
  • Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator
  • Any reason for which the investigator, upon her evaluation, feels that it is in the subject's best interest not to continue on in the study.
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00739024
CRC 0690
No
Swedish Medical Center
Swedish Medical Center
Takeda
Principal Investigator: Sheena K Aurora, MD Swedish Medical Center
Swedish Medical Center
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP